Bladder cancer (Homo sapiens)
From WikiPathways
Description
The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinomas are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumors arise and evolve through divergent phenotypic pathways. Some tumors progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumors. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumors, or they arise de novo as invasive tumors. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumor microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF). Phosphorylation sites were added based on information from PhosphoSitePlus (R), https://www.phosphosite.org.
Proteins on this pathway have targeted assays available via the CPTAC Assay Portal
Quality Tags
Ontology Terms
Saving...Bibliography
View all... |
- Williams SV, Hurst CD, Knowles MA; ''Oncogenic FGFR3 gene fusions in bladder cancer.''; Hum Mol Genet, 2013 PubMed Europe PMC Scholia
- Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E; ''PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.''; Nucleic Acids Res, 2015 PubMed Europe PMC Scholia
- Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hأ©rault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y; ''PI3K/AKT pathway activation in bladder carcinogenesis.''; Int J Cancer, 2014 PubMed Europe PMC Scholia
- Juanpere N, Agell L, Lorenzo M, de Muga S, Lأ³pez-Vilarأ³ L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernأ،ndez S; ''Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.''; Hum Pathol, 2012 PubMed Europe PMC Scholia
- di Martino E, Tomlinson DC, Knowles MA; ''A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.''; Adv Urol, 2012 PubMed Europe PMC Scholia
- ''Bladder Cancer Pathway''; http://www.genome.jp/dbget-bin/www_bget?pathway:map05219,
- Wolf EM, Liang G, Jones PA; ''Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.''; http://www.ncbi.nlm.nih.gov/pubmed/16474624, 2005 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
Annotated Interactions
No annotated interactions
